Aleena Banerji1. 1. Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: abanerji@partners.org.
Abstract
OBJECTIVE: Hereditary angioedema (HAE) is a rare genetic disease characterized by long-term recurrent attacks of subcutaneous or submucosal edema in different parts of the body. A comprehensive review of the literature on burden of illness for patients with HAE is presented. DATA SOURCES: A Boolean search was performed using MEDLINE and EMBASE databases and the Internet. STUDY SELECTION: Articles discussing aspects of the burden of illness in HAE were selected. Topics focused on the course of the disease, nature of attacks, treatment, quality of life, and costs. RESULTS: Hereditary angioedema is associated with a significant and multifaceted disease burden. Diagnosis is often delayed for years, with patients receiving ineffective treatment and unnecessary medical procedures before diagnosis. HAE attacks are painful, unpredictable, and debilitating and often require emergency medical attention. Attacks can affect a patient's daily activities, including work or schooling. Depression and anxiety are prevalent in patients with HAE. Recent advances in treatment provide patients with effective and well-tolerated prophylactic and on-demand therapeutic options. However, end points specific to HAE that better measure the impact of treatment on disease burden are lacking. Furthermore, there is a notable paucity of literature directed toward physicians who are instrumental in diagnosing and treating patients with HAE (eg, emergency department). CONCLUSION: More publications are broadening the understanding of HAE. However, important gaps remain. Effective management of HAE requires a more comprehensive understanding of the disease burden so that disease management can be individualized to meet specific patient needs.
OBJECTIVE:Hereditary angioedema (HAE) is a rare genetic disease characterized by long-term recurrent attacks of subcutaneous or submucosal edema in different parts of the body. A comprehensive review of the literature on burden of illness for patients with HAE is presented. DATA SOURCES: A Boolean search was performed using MEDLINE and EMBASE databases and the Internet. STUDY SELECTION: Articles discussing aspects of the burden of illness in HAE were selected. Topics focused on the course of the disease, nature of attacks, treatment, quality of life, and costs. RESULTS:Hereditary angioedema is associated with a significant and multifaceted disease burden. Diagnosis is often delayed for years, with patients receiving ineffective treatment and unnecessary medical procedures before diagnosis. HAE attacks are painful, unpredictable, and debilitating and often require emergency medical attention. Attacks can affect a patient's daily activities, including work or schooling. Depression and anxiety are prevalent in patients with HAE. Recent advances in treatment provide patients with effective and well-tolerated prophylactic and on-demand therapeutic options. However, end points specific to HAE that better measure the impact of treatment on disease burden are lacking. Furthermore, there is a notable paucity of literature directed toward physicians who are instrumental in diagnosing and treating patients with HAE (eg, emergency department). CONCLUSION: More publications are broadening the understanding of HAE. However, important gaps remain. Effective management of HAE requires a more comprehensive understanding of the disease burden so that disease management can be individualized to meet specific patient needs.
Authors: Aleena Banerji; Paula Busse; Sandra C Christiansen; Henry Li; William Lumry; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony Castaldo; Janet F Long; Bruce L Zuraw; Marc Riedl Journal: Allergy Asthma Proc Date: 2015 May-Jun Impact factor: 2.587
Authors: Ting Qiu; Maria J Chiuchiolo; Adele S Whaley; Anthony R Russo; Dolan Sondhi; Stephen M Kaminsky; Ronald G Crystal; Odelya E Pagovich Journal: Allergy Date: 2019-03-19 Impact factor: 13.146
Authors: William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer Journal: Allergy Date: 2020-12-24 Impact factor: 13.146
Authors: H J Longhurst; M D Tarzi; F Ashworth; C Bethune; C Cale; J Dempster; M Gompels; S Jolles; S Seneviratne; C Symons; A Price; D Edgar Journal: Clin Exp Immunol Date: 2015-05-13 Impact factor: 4.330
Authors: Aleena Banerji; Murat Baş; Jonathan A Bernstein; Isabelle Boccon-Gibod; Maria Bova; John Dempster; Anete Sevciovic Grumach; Markus Magerl; Kimberly Poarch; Manuel Branco Ferreira Journal: Allergy Rhinol (Providence) Date: 2016-09-22